Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda

The malaria vaccine BK-SE36 is a recombinant protein (SE36) based on the Honduras 1 serine repeat antigen-5 of Plasmodium falciparum, adsorbed to aluminium hydroxide gel. The phase Ib trial in Uganda demonstrated the safety and immunogenicity of BK-SE36. Ancillary analysis in the follow-up study of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Rep
Prif Awduron: Yagi, Masanori, Palacpac, Nirianne M. Q., Ito, Kazuya, Oishi, Yuko, Itagaki, Sawako, Balikagala, Betty, Ntege, Edward H., Yeka, Adoke, Kanoi, Bernard N., Katuro, Osbert, Shirai, Hiroki, Fukushima, Wakaba, Hirota, Yoshio, Egwang, Thomas G., Horii, Toshihiro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050508/
https://ncbi.nlm.nih.gov/pubmed/27703240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep34363
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg